Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Resection surgery
PROCEDURE
3 trials
Sponsors
H. Lee Moffitt Cancer Center and Research Institute
, Xuanwu Hospital, Beijing
, Radboud University Medical Center
Conditions
Chordoma of Spine
HER2-positive Breast Cancer
Pancreatic Cancer
Rectal Cancer
Surgery
Phase 1
Multimodal Imaging in Rectal Cancer & Pancreatic Cancer
NCT06395337
Radboud University Medical Center
Pancreatic Cancer, Rectal Cancer
Start: 2024-05-02
End: 2025-06-02
Target: 20
Updated: 2024-05-02
Phase 2
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
Recruiting
NCT05325632
H. Lee Moffitt Cancer Center and Research Institute
HER2-positive Breast Cancer
Start: 2021-10-28
End: 2027-09-01
Target: 53
Updated: 2026-03-02
Unknown Phase
A Prospective Study of Surgical Treatment Strategies for Chordoma
NCT05707767
Xuanwu Hospital, Beijing
Chordoma of Spine, Surgery
Start: 2023-02-01
End: 2024-09-30
Target: 100
Updated: 2023-07-19
Related Papers
Intratumoral dendritic cell (DC1) therapy prior to neoadjuvant chemotherapy in HER2-positive breast cancer (NATASHA trial).
Journal of Clinical Oncology
2026-05-27
Outcomes After Intratumoral Delivery of Immunotherapy in Breast Cancer.
2026-05-13
A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer
npj Breast Cancer
2025-03-17
5 citations
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in <i>ERBB2</i> Breast Cancer
JAMA Oncology
2024-12-05
3 citations
A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC).
Journal of Clinical Oncology
2024-06-01
1 citations
Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial.
Journal of Clinical Oncology
2023-06-01
1 citations